September 2022

Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials

• Abdulazeez Salawu,
• Alberto Hernando-Calvo,
• Rachel Y. Chen,
• ...
• Marc Oliva,
• Zhihui A. Liu,
• Lillian L. Siu

Overdiagnosis of invasive breast cancer in population-based breast cancer screening: A short- and long-term perspective

• Lilu Ding,
• Keris Poelhekken,
• Marcel J.W. Greuter,
• ...
• Nehmat Houssami,
• Guido Van Hal,
• Geertruida H. de Bock

Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer

• Katrin Almstedt,
• Anne-Sophie Heimes,
• Franziska Kappenberg,
• ...
• Jan G. Hengstler,
• Annette Hasenburg,
• Marcus Schmidt

Estimating long-term mortality in women with hormone receptor-positive breast cancer: The ‘ESTIMATE’ tool

• José P. Leone,
• Noah Graham,
• Sara M. Tolaney,
• ...
• Eric P. Winer,
• Nancy U. Lin,
• Nabihah Tayob

Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy

• Richard A. Anderson,
• Matteo Lambertini,
• Peter S. Hall,
• W. Hamish Wallace,
• David S. Morrison,
• Tom W. Kelsey

Incorporating progesterone receptor expression into the PREDICT breast prognostic model

• Isabelle Grootes,
• Renske Keeman,
• Fiona M. Blows,
• ...
• Marjanka K. Schmidt,
• Montserrat García-Closas,
• Paul D.P. Pharoah

First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements

• Yuxiang Ma,
• Hongyun Zhao,
• Jinhui Xue,
• ...
• Wenfeng Fang,
• Su Li,
• Li Zhang

Microsatellite instability and sex differences in resectable gastric cancer – A pooled analysis of three European cohorts

• Alexander Quaas,
• Hedde D. Biesma,
• Anna D. Wagner,
• ...
• Bauke Ylstra,
• Hanneke W.M. van Laarhoven,
• Nicole C.T. van Grieken

A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma – The Taiwan Cooperative Oncology Group T1217 study

• Li-Yuan Bai,
• Chung-Pin Li,
• Yan-Shen Shan,
• ...
• Chang-Fang Chiu,
• Tsang-Wu Liu,
• Li-Tzong Chen

First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer – Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110)

• Arndt Stahler,
• Dominik P. Modest,
• Ludwig Fischer von Weikersthal,
• ...
• Andreas Jung,
• Sebastian Stintzing,
• Volker Heinemann

FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases – The PARLIM trial (AIO KRK 0314)

• Dominik Paul Modest,
• Meinolf Karthaus,
• Stefan Kasper,
• ...
• Andreas Jung,
• Sebastian Stintzing,
• Volker Heinemann

Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis

• Chiara Ciccarese,
• Roberto Iacovelli,
• Cora N. Sternberg,
• Silke Gillessen,
• Giampaolo Tortora,
• Karim Fizazi

Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial

• Joan Carles,
• Teresa Alonso-Gordoa,
• Begoña Mellado,
• ...
• Miguel Sampayo-Cordero,
• Andrea Malfettone,
• Javier Garde

Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference

• Farzana Pashankar,
• Krisztina Hanley,
• Michelle Lockley,
• ...
• Thomas M. Ulbright,
• Lindsay Frazier,
• Michelle S. Hirsch

Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)

• Takuya Higashiyama,
• Kiminori Sugino,
• Hisato Hara,
• ...
• Hideaki Kaneda,
• Iwao Sugitani,
• Makoto Tahara

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria

• James Larkin,
• Jeffrey Weber,
• Michele Del Vecchio,
• ...
• Margarita Askelson,
• Paolo A. Ascierto,
• Mario Mandalá

Model soups improve performance of dermoscopic skin cancer classifiers

• Roman C. Maron,
• Achim Hekler,
• Sarah Haggenmüller,
• ...
• Daniel B. Lipka,
• Eva Krieghoff-Henning,
• Titus J. Brinker

Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours

Long-term follow-up of nilotinib in TGCT

• Geert Spierenburg,
• Peter Grimison,
• Christine Chevreau,
• ...
• Michiel A.J. van de Sande,
• Jean-Yves Blay,
• Hans Gelderblom

Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas

ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

• Andrew DJ. Pearson,
• Nathalie Gaspar,
• Katherine Janeway,
• ...
• Vickie Buenger,
• Gregory Reaman,
• Gilles Vassal

Tankyrase-selective inhibitor STP1002 shows preclinical antitumour efficacy without on-target toxicity in the gastrointestinal tract

• Dong Young Kim,
• Young-Ju Kwon,
• Won Yong Seo,
• ...
• Hyung Tae Bang,
• Kyungjin Kim,
• Jae-Sung Kim

The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis

• Liesbeth M. Hondelink,
• Anne M.R. Schrader,
• Golzar Asri Aghmuni,
• ...
• Judith V.M.G. Bovee,
• Tom van Wezel,
• Danielle Cohen

MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients

• Mathilde Saint-Ghislain,
• Anne-Céline Derrien,
• Lionnel Geoffrois,
• ...
• Sophie Piperno-Neumann,
• Marc-Henri Stern,
• Manuel Rodrigues

Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trials

• Patricia Martin-Romano,
• Leo Colmet-Daage,
• Daphne Morel,
• ...
• Antoine Hollebecque,
• Christophe Massard,
• Sophie Postel-Vinay

Influence of the SARS-CoV-2 outbreak on management and prognosis of new lung cancer cases, a retrospective multicentre real-life cohort study

• Sonia Priou,
• Guillaume Lamé,
• Gérard Zalcman,
• ...
• Christophe Tournigand,
• Emmanuelle Kempf
• on behalf of the Assistance Publique – Hôpitaux de Paris (AP-HP) Cancer Group

What should be done in terms of fertility preservation for patients with cancer? The French 2021 guidelines

• Nathalie Rives,
• Blandine Courbière,
• Thierry Almont,
• ...
• Fadila Farsi,
• Catherine Poirot,
• Éric Huyghe

Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis

• James A. Thomas,
• Bradley J. Kendall,
• Christine Dalais,
• Graeme A. Macdonald,
• Aaron P. Thrift

Exposure to artificial light at night: A common link for obesity and cancer?

• Giovanna Muscogiuri,
• Eleonora Poggiogalle,
• Luigi Barrea,
• ...
• Silvia Savastano,
• Annamaria Colao
• on behalf of the Obesity Programs of nutrition, Education, Research and Assessment (OPERA) group

Nivolumab induces long-term remission in a patient with fusariosis

• Elham Khatamzas,
• Sibylle C. Mellinghoff,
• Martin Thelen,
• ...
• Karl Dichtl,
• Steffen Ormanns,
• Michael von Bergwelt-Baildon

Three-year disease-free remission in a xeroderma pigmentosum patient after adjuvant anti-PD-1 therapy

• Valerie Scheer,
• Oliver Schmalz,
• Percy Lehmann,
• Silke C. Hofmann,
• Ulrich Wesselmann